AUPP823999A0 - A treatment - Google Patents

A treatment

Info

Publication number
AUPP823999A0
AUPP823999A0 AUPP8239A AUPP823999A AUPP823999A0 AU PP823999 A0 AUPP823999 A0 AU PP823999A0 AU PP8239 A AUPP8239 A AU PP8239A AU PP823999 A AUPP823999 A AU PP823999A AU PP823999 A0 AUPP823999 A0 AU PP823999A0
Authority
AU
Australia
Prior art keywords
chaperonin
ifn
beta
treatment
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP8239A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Priority to AUPP8239A priority Critical patent/AUPP823999A0/en
Publication of AUPP823999A0 publication Critical patent/AUPP823999A0/en
Priority to KR1020017009163A priority patent/KR100694011B1/ko
Priority to AU25271/00A priority patent/AU771867B2/en
Priority to EP00903434A priority patent/EP1150703B1/en
Priority to PCT/AU2000/000032 priority patent/WO2000043033A1/en
Priority to ES00903434T priority patent/ES2255484T3/es
Priority to DE60024967T priority patent/DE60024967T2/de
Priority to JP2000594486A priority patent/JP4691257B2/ja
Priority to DK00903434T priority patent/DK1150703T3/da
Priority to AT00903434T priority patent/ATE313332T1/de
Priority to PT00903434T priority patent/PT1150703E/pt
Priority to CA2361081A priority patent/CA2361081C/en
Priority to US12/362,456 priority patent/US20090214473A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
AUPP8239A 1999-01-20 1999-01-20 A treatment Abandoned AUPP823999A0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
CA2361081A CA2361081C (en) 1999-01-20 2000-01-20 Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
DE60024967T DE60024967T2 (de) 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose
AU25271/00A AU771867B2 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis
EP00903434A EP1150703B1 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS
ES00903434T ES2255484T3 (es) 1999-01-20 2000-01-20 Terapia con chaperonina 10 y beta-interferon para la esclesosis multiple.
KR1020017009163A KR100694011B1 (ko) 1999-01-20 2000-01-20 다발성 경화증의 샤페로닌 10 및 베타-인터페론 치료법
JP2000594486A JP4691257B2 (ja) 1999-01-20 2000-01-20 シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法
DK00903434T DK1150703T3 (da) 1999-01-20 2000-01-20 Behandling af multipel sclerose med chaperonin 10 og beta-interferon
AT00903434T ATE313332T1 (de) 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose
PT00903434T PT1150703E (pt) 1999-01-20 2000-01-20 Terapia de esclerose multipla com chaperonina 10 e beta-interferao
US12/362,456 US20090214473A1 (en) 1999-01-20 2009-01-29 Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment

Publications (1)

Publication Number Publication Date
AUPP823999A0 true AUPP823999A0 (en) 1999-02-11

Family

ID=3812443

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPP8239A Abandoned AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
AU25271/00A Ceased AU771867B2 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU25271/00A Ceased AU771867B2 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis

Country Status (12)

Country Link
US (1) US20090214473A1 (OSRAM)
EP (1) EP1150703B1 (OSRAM)
JP (1) JP4691257B2 (OSRAM)
KR (1) KR100694011B1 (OSRAM)
AT (1) ATE313332T1 (OSRAM)
AU (2) AUPP823999A0 (OSRAM)
CA (1) CA2361081C (OSRAM)
DE (1) DE60024967T2 (OSRAM)
DK (1) DK1150703T3 (OSRAM)
ES (1) ES2255484T3 (OSRAM)
PT (1) PT1150703E (OSRAM)
WO (1) WO2000043033A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
KR20080098579A (ko) 2005-08-31 2008-11-11 씨바이오 리미티드 변형된 샤페로닌 10
KR20080075505A (ko) * 2005-10-20 2008-08-18 씨바이오 리미티드 과민증의 치료 방법
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
DE60024967D1 (en) 2006-01-26
ATE313332T1 (de) 2006-01-15
EP1150703B1 (en) 2005-12-21
EP1150703A1 (en) 2001-11-07
DK1150703T3 (da) 2006-05-29
US20090214473A1 (en) 2009-08-27
EP1150703A4 (en) 2004-11-10
KR20020002376A (ko) 2002-01-09
DE60024967T2 (de) 2006-08-17
AU771867B2 (en) 2004-04-01
JP4691257B2 (ja) 2011-06-01
CA2361081C (en) 2010-09-21
AU2527100A (en) 2000-08-07
CA2361081A1 (en) 2000-07-27
JP2002535286A (ja) 2002-10-22
PT1150703E (pt) 2006-05-31
ES2255484T3 (es) 2006-07-01
WO2000043033A1 (en) 2000-07-27
KR100694011B1 (ko) 2007-03-12

Similar Documents

Publication Publication Date Title
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AU7031500A (en) Therapeutic quinazoline compounds
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
AU5906398A (en) Dosage composition for nasal delivery and method of use of the same
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
AU6529796A (en) Biological agent compositions
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
AU4170197A (en) Pharmaceutical compounds
GR3006815T3 (OSRAM)
EP1105407A4 (en) AMINOSTEROL DERIVATIVES AND THEIR USE
GB9907571D0 (en) Compounds
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
EP0744176A3 (en) Methods for inhibiting bone loss
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
CA2293808A1 (en) Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
AU1469097A (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 2527100

Country of ref document: AU